Faslodex Name Confusion Not Prevented By Differences In Dosage Form - FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Differences in dosage form or administration routes do not always prevent confusion of similar drug names, FDA’s Division of Medication Errors & Technical Support suggests in review documents for AstraZeneca’s breast cancer drug Faslodex.